Protalix BioTherapeutics, Inc. (PLX)
NYSEAMERICAN: PLX · Real-Time Price · USD
2.830
+0.040 (1.43%)
At close: Mar 13, 2026, 4:00 PM EDT
2.830
0.00 (0.00%)
After-hours: Mar 13, 2026, 8:00 PM EDT
Protalix BioTherapeutics Employees
Protalix BioTherapeutics had 213 employees as of December 31, 2024. The number of employees increased by 5 or 2.40% compared to the previous year.
Employees
213
Change (1Y)
5
Growth (1Y)
2.40%
Revenue / Employee
$290,329
Profits / Employee
$25,324
Market Cap
227.59M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2024 | 213 | 5 | 2.40% | 213 | 0 |
| Dec 31, 2023 | 208 | 11 | 5.58% | 208 | 0 |
| Dec 31, 2022 | 197 | -9 | -4.37% | 193 | 4 |
| Dec 31, 2021 | 206 | -1 | -0.48% | 202 | 4 |
| Dec 31, 2020 | 207 | 11 | 5.61% | 207 | 0 |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| MacroGenics | 341 |
| Humacyte | 220 |
| MediWound | 121 |
| Arcturus Therapeutics Holdings | 111 |
| Keros Therapeutics | 78 |
| Cartesian Therapeutics | 75 |
| Sol-Gel Technologies | 34 |
| Elicio Therapeutics | 32 |
PLX News
- 2 days ago - Protalix BioTherapeutics to Announce Fiscal Year 2025 Financial Results and Business Update on March 18, 2026 - PRNewsWire
- 4 days ago - Chiesi Global Rare Diseases and Protalix BioTherapeutics Announce European Commission Approval of Additional Dosing Regimen of Every Four Weeks for Elfabrio® (pegunigalsidase alfa) - GlobeNewsWire
- 5 weeks ago - A March Decision That Could Change Protalix BioTherapeutics Outlook - Seeking Alpha
- 6 weeks ago - Chiesi Global Rare Diseases and Protalix BioTherapeutics Receive Positive CHMP Opinion for an Additional Dosing Regimen of Every Four Weeks for Elfabrio® (pegunigalsidase alfa) in the EU - GlobeNewsWire
- 6 weeks ago - Chiesi Global Rare Diseases and Protalix BioTherapeutics Receive Positive CHMP Opinion for an Additional Dosing Regimen of 2mg/kg Body Weight Every-Four-Weeks for Elfabrio® (pegunigalsidase alfa) ▼ in the EU - GlobeNewsWire
- 2 months ago - Protalix BioTherapeutics Letter to Stockholders - PRNewsWire
- 3 months ago - Protalix Biotherapeutics and Secarna Pharmaceuticals Enter into Collaboration and Option Agreement - PRNewsWire
- 4 months ago - Protalix BioTherapeutics, Inc. (PLX) Q3 2025 Earnings Call Transcript - Seeking Alpha